This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The Drug Risk Resource Center is the Web’s latest source for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com
New York, NY (PRWEB) November 20, 2012
A report issued by the Institute for Safe Medicine Practices’ QuarterWatch (PDF) on October 3, 2012 estimates that prescription drug complaints to the FDA have risen 90% in the past 4 years, and two drugs, Pradaxa and Chantix, are responsible for 37% of that increase.
Judge David Herndon, who is overseeing the ongoing Pradaxa bleeding litigation in a federal MDL Court, recently ordered that German drug maker Boehringer Ingelheim will have to provide access to its foreign witnesses and documents, according to a Case Management Order Regarding Foreign Defendants and Direct Filing signed on October 20, 2012. http://www.ilsd.uscourts.gov/opinions/ilsd_live.3.12.md.2385.2184887.0.pdf#search=%22pradaxa%22
The report comes as The Journal for The American Medical Association last month warned that the FDA may have rushed approval of Pradaxa, overlooking key Pradaxa side effects like internal bleeding. The FDA warned on December 7, 2011 that it was investigating Pradaxa after receiving more injury or death reports than expected.
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.
While all anticoagulants can cause internal bleeding, the Journal of Neurosurgery reported doctors’ concerns on March 6, 2012 that, once Pradaxa causes internal bleeding, there is little they can do to stop it.
Judge Herndon previously issued an order on July 24, 2012 that those injured by Pradaxa can proceed with lawsuits. Due to the number of Pradaxa lawsuits expected, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-internal/bleeding-risk/prweb10150453.htm